On March 8, Cantel Medical
- Revenues increased by 9.1%, primarily led by improvement in the company's core infection prevention and control business.
- Cantel showed strong bottom-line performance, with a 20% rise in income from continuing operations.
- The company benefited from its investments in direct sales and service in endoscope reprocessing and supply-chain efficiencies in the recently started water purification segment.
- R. Scott Jones was appointed as the new CEO and president.
(Figures in millions, except per-share data.)
Income Statement Highlights
Q2 2007 |
Q2 2006 |
Change |
|
---|---|---|---|
Sales |
$51.6 |
$47.3 |
9.1% |
Net Profit* |
$2.3 |
$1.9 |
20.2% |
EPS |
$0.14 |
$0.11 |
27.3% |
Diluted Shares |
16.1 |
16.4 |
(1.9%) |
Get back to basics with the income statement.
Margin Checkup
Q2 2007 |
Q2 2006 |
Change* |
|
---|---|---|---|
Gross Margin |
37.8% |
35.6% |
2.2 |
Operating Margin |
8.7% |
8.5% |
0.2 |
Net Margin |
4.4% |
4.0% |
0.4 |
Margins are the earnings engine.
Balance Sheet Highlights
Assets |
Q2 2007 |
Q2 2006 |
Change |
---|---|---|---|
Cash + ST Invest. |
$16.7 |
$19.7 |
(15.2%) |
Accounts Rec. |
No Data |
No Data |
No Data |
Inventory |
No Data |
No Data |
No Data |
Liabilities |
Q2 2007 |
Q2 2006 |
Change |
---|---|---|---|
Accounts Payable |
No Data |
No Data |
No Data |
Long-Term Debt |
$36.0 |
$61.5 |
(41.5%) |
The balance sheet reflects the company's health.
Cash Flow Highlights
Free cash flow is a Fool's best friend.
Related Foolishness:
- Smith & Nephew, What's the Deal?
- Only One Bone to Pick With Stryker
- Less Support for Drug-Eluting Stents?
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.